This validates our existing thesis:
AI will be central to science, but its impact depends on researchers having simple access to compute, the right models, and infrastructure they can actually use.
That is the direction AxonDAO is building for.
Introducing GPT-Rosalind, our frontier reasoning model built to support research across biology, drug discovery, and translational medicine.